INC.

Calviri Scientists Find New Class of Biomarkers for Predicting Treatment Response in Cancer Patients

by

Newly observed anti-FSP antibodies also found to predict immune-related adverse events PHOENIX, May 23, 2023 /PRNewswire/ — Scientists studying immune checkpoint inhibitor (ICI) therapies in advanced lung cancer patients have found that a new class of blood-based biomarkers— anti-frameshift peptide antibodies, or anti-FSP antibodies— could be developed into improved or orthogonal tests for predicting tumor … Read more

Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System

by

Chief Medical Officer Provides Overview of Preclinical Data Recently Presented at the 2023 American Association of Cancer Research (AACR) annual meeting Video Highlights Validation of the ONCOPREX® Nanoparticle Delivery System with a Second Tumor Suppressor Gene AUSTIN, Texas, May 23, 2023 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company … Read more

Ecological Laboratories Announces Effective Solution for Sargassum Odor Reduction and Composting

by

CAPE CORAL, Fla., May 23, 2023 /PRNewswire/ — Ecological Laboratories, a leading developer of sustainable solutions for environmental challenges, announces an effective solution for Sargassum odor reduction and composting. Ecological utilizes shelf-stable bacterial consortium mainly Rhodopseudomonas and Wolinella bacteria to significantly reduce the unpleasant odor and enhance the composting process of Sargassum seaweed. This innovative … Read more

CORVIA MEDICAL PUBLIE LES RÉSULTATS D’UN ESSAI CLINIQUE DE DEUX ANS CONFIRMANT LE BÉNÉFICE DURABLE ET LA SÉCURITÉ DE SON SHUNT AURICULAIRE CHEZ LES PATIENTS SOUFFRANT D’INSUFFISANCE CARDIAQUE USA – Français USA – español USA – Deutsch

by

LE PREMIER ESSAI CONTRÔLÉ RANDOMISÉ DE PHASE III SUR LA THÉRAPIE DE SHUNT AURICULAIRE RESTE PROMETTEUR TEWKSBURY, Massachusetts, 23 mai 2023 /PRNewswire/ — Corvia Medical, Inc, une société dédiée à la transformation du traitement de l’insuffisance cardiaque, a annoncé aujourd’hui les résultats à deux ans de son essai clinique randomisé REDUCE LAP-HF II, confirmant l’innocuité et l’efficacité soutenue du … Read more

CORVIA MEDICAL VERÖFFENTLICHT DIE ERGEBNISSE DER ZWEI JAHRE DAUERNDEN CLINICAL TRIAL, DIE DEN NUTZEN UND DIE SICHERHEIT DES ATRIALEN SHUNTS BEI PATIENTEN MIT HERZVERSAGEN BESTÄTIGEN USA – Deutsch USA – español

by

ERSTE RANDOMISIERTE, KONTROLLIERTE PHASE-III-STUDIE ZUR VORHOF-SHUNT-THERAPIE ZEIGT WEITERHIN VIELVERSPRECHENDE ERGEBNISSE  TEWKSBURY, Massachusetts, 23. Mai 2023 /PRNewswire/ — Corvia Medical, Inc., ein Unternehmen, das die Behandlung der Herzinsuffizienz revolutionieren will, gab heute die Zweijahresergebnisse der randomisierten klinischen Studie REDUCE LAP-HF II bekannt, die die Sicherheit und nachhaltige Wirksamkeit des Corvia® Atrial Shunt bei entsprechend ausgewählten Herzinsuffizienzpatienten mit … Read more

Rakuten Medical to Start a Global Phase 3 Trial of Alluminox™ Treatment using ASP-1929 for Recurrent Head and Neck Cancer in India

by

SAN DIEGO, May 22, 2023 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox™ platform, today announced that the Company has been granted permission from the Indian Central Drugs Standard Control Organization (CDSCO) to conduct its global, pivotal Phase 3 clinical trial (ASP-1929-301/ClinicalTrials.gov … Read more

Endotronix annonce à nouveau des résultats positifs en publiant les données à 12 mois de l’essai SIRONA 2, portant sur la gestion à distance de l’insuffisance cardiaque à l’aide du capteur de l’artère pulmonaire Cordella USA – Français USA – English USA – English USA – Deutsch USA – español

by

L’étude a atteint ses paramètres secondaires et l’utilisation à long terme des capteurs a été associée à des améliorations importantes des paramètres de qualité de vie des patients, ainsi qu’à de faibles taux d’événements d’hospitalisation et de décès liés à l’insuffisance cardiaque. LISLE, ILLINOIS, 23 mai 2023 /PRNewswire/ — Endotronix, Inc.,une entreprise de santé numérique … Read more

Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence

by

Nalbuphine ER resulted in a rapid and marked reduction in recorded daytime cough among patients suffering from IPF-related cough The mean change in 24-hour objective cough frequency was similar in patients with concomitant anti-fibrotic therapy and without concomitant anti-fibrotic therapy NEW HAVEN, Conn., May 22, 2023 /PRNewswire/ — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical … Read more

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

by

SAN DIEGO, May 22, 2023 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on May 20, 2023, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 36,900 shares of … Read more